Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.
EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.